Cetuximab
- Generic Name
- Cetuximab
- Brand Names
- Erbitux
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 205923-56-4
- Unique Ingredient Identifier
- PQX0D8J21J
- Background
Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible for regulating epithelia...
- Indication
Cetuximab indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy. It is indicated for treating a recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil. It is indicated for r...
- Associated Conditions
- Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN), Metastatic Colorectal Cancer (CRC), Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Regionally Advanced Squamous Cell Carcinoma of the Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Associated Therapies
- -
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 542
- Registration Number
- NCT04929223
- Locations
- 🇺🇸
cCare, Encinitas, California, United States
🇺🇸Los Angeles Cancer Network, Los Angeles, California, United States
🇺🇸Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
NBTXR3 With or Without Cetuximab in LA-HNSCC
- Conditions
- Interventions
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Nanobiotix
- Target Recruit Count
- 500
- Registration Number
- NCT04892173
- Locations
- 🇺🇸
Memorial Radiation Oncology Medical Group - Laguna Hills, Long Beach, California, United States
🇺🇸Hoag Hospital Newport Beach, Newport Beach, California, United States
🇺🇸CHRISTUS - St. Vincent Regional Cancer Center, Santa Fe, New Mexico, United States
Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer
- First Posted Date
- 2021-04-21
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 7
- Registration Number
- NCT04853043
- Locations
- 🇺🇸
Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah, United States
🇺🇸Intermountain Medical Center, Salt Lake City, Utah, United States
c-CetuIRI Versus Ersecond-line Irinotecan s-IRI-CetuIRI
- First Posted Date
- 2021-04-06
- Last Posted Date
- 2021-04-06
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 120
- Registration Number
- NCT04833036
- Locations
- 🇨🇳
Fudan University Cancer Hospital, ShangHai, Shanghai, China
FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases
- Conditions
- Interventions
- First Posted Date
- 2021-04-06
- Last Posted Date
- 2021-04-06
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 160
- Registration Number
- NCT04832776
- Locations
- 🇨🇳
Department of Colorectal Surgery Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
PF-07284892 in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-03-16
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 53
- Registration Number
- NCT04800822
- Locations
- 🇺🇸
Brigitte Harris Cancer Pavilion, Detroit, Michigan, United States
🇺🇸Mayo Clinic in Arizona - Phoenix, Phoenix, Arizona, United States
🇺🇸Mayo Clinic, Scottsdale, Arizona, United States
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
- Conditions
- Interventions
- First Posted Date
- 2021-03-11
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 461
- Registration Number
- NCT04793958
- Locations
- 🇺🇸
Local Institution - 010-872-B, Denver, Colorado, United States
🇺🇸Local Institution - 010-872-J, Lakewood, Colorado, United States
🇺🇸Local Institution - 010-872-F, Littleton, Colorado, United States
Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-03-10
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 37
- Registration Number
- NCT04790448
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB
- First Posted Date
- 2021-03-02
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Azienda Unità Sanitaria Locale Reggio Emilia
- Target Recruit Count
- 280
- Registration Number
- NCT04776655
- Locations
- 🇮🇹
Azienda ULSS 3 Serenissima, Mirano, VE, Italy
🇮🇹Ospedale Civile di Guastalla, Guastalla, Reggio Emilia, Italy
🇮🇹Ospedale San Salvatore, Coppito, L'Aquila, Italy
A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-01-25
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT04722523
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.